ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Prediabetic State
Non-alcoholic Fatty Liver Disease
Type 2 Diabetes Mellitus

Interventions

DRUG: Cenicriviroc 150 mg
DRUG: Placebo

Sponsor

Tobira Therapeutics, Inc.